Business
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models. SAN DIEGO, Nov. 13, 2023 (GLOBE
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models.\nSAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation for its lead therapeutic candidate, efzofitimod, at the American College of Rheumatology (ACR) Convergence 2023, which is being held November 10 – 15, 2023, in San Diego, CA. “These data highlight the broad anti-inflammatory potential of efzofitimod in treating immune-driven conditions and strengthen the evidence that neuropilin-2 (NRP2) is an important immune regulator,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Although we remain highly focused on our current clinical development program for efzofitimod in interstitial lung disease (ILD), which includes pulmonary sarcoidosis and systemic sclerosis (SSc or scleroderma)-related ILD, this data provides further evidence regarding the potential broader application of efzofitimod in inflammatory diseases beyond these respiratory conditions.” Details of the presentation appear below. The poster will be available on the aTyr website once presented. Title: Efzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical ModelsSession Title: RA – Treatment Poster IISession Format: Poster PresentationPoster Number: 1322Date and Time: Monday, November 13, 2023, from 9:00 a.m. to 11:00 a.m. PSTLocation: Poster Hall, San Diego Convention Center The poster presents findings from preclinical models of rheumatoid arthritis (RA) and RA-associated ILD (RA-ILD), where NRP2, efzofitimod’s binding partner, is known to be expressed on pro-inflammatory synovial macrophages. An animal knockout model for NRP2 demonstrated that NRP2 deficiency exacerbated disease pathology in preclinical models of inflammatory disease. In a model of collagen-induced RA, efzofitimod treatment lowered disease severity and improved remission. Furthermore, in a transgenic mouse model for RA-ILD, treatment with efzofitimod led to a reduction in the number of pro-inflammatory immune cell populations in the lungs and exhibited ...